Form D · Biotechnology
Akston Biosciences Corp
Beverly, MA · CIK 0001776612
Offering snapshot reported Apr 15, 2022 · SEC filing
- Reported sold
- $5.16M Offering amount: $10M
- Investors reported
- 37 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 10, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 15, 2022 | Initial | $5,162,723 | No comparison | 37 | SEC filing |
| Jun 9, 2021 | Amendment | $7,876,894 | $4,488,303vs Dec 30, 2020 | 71 | SEC filing |
| Jun 1, 2021 | Initial | $1,000,029 | No comparison | Not reported | SEC filing |
| Dec 30, 2020 | Initial | $3,388,591 | No comparison | 32 | SEC filing |
| May 12, 2020 | Initial | $5,101,514 | No comparison | 71 | SEC filing |
| Jun 20, 2019 | Initial | $2,532,500 | No comparison | 46 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-442035
Source: Form D, filed Apr 15, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lovick E. Cannon | Director |
| Robyn Davis | Director |
| James M. Herriman | Executive |
| Thomas M. Lancaster | Director, Executive |
| Todd C. Zion | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 Cummings Center Suite 454 C
Beverly, MA, 01915
Beverly, MA, 01915